2RH Stock Chart & Stats
€8.00
€0.00(0.00%)
At close: 4:00 PM EDT
€8.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€7.33 - €8.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.79M
Enterprise Value€0.69
Total Cash (Recent Filing)€2.87M
Total Debt (Recent Filing)€214.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Mar 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding6,080,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€43.92M
Bulls Say, Bears Say
Bulls Say
Established GI ProductsThe rights to two established, FDA-approved GI products give RedHill a larger commercial base than its recent reported revenue suggests. Their existing sales history and broad payer coverage may support faster revenue scaling and a more durable platform for additional product acquisitions.
Portfolio MonetizationSelling Talicia converted an existing asset into substantial upfront liquidity while preserving potential milestone payments. Redeploying part of those proceeds into established GI products represents a clearer portfolio strategy and may improve the company’s ability to fund commercial expansion.
Improved Balance SheetLower debt and a return to positive equity improve RedHill’s solvency position relative to prior years. Although the improvement needs to prove consistent, reduced leverage can provide greater financial flexibility as the company transitions toward a broader commercial product portfolio.
Bears Say
Revenue CollapseThe sharp revenue contraction shows that RedHill’s prior commercial base was not durable through 2025. Rebuilding sales through Rebyota and Clenpiq will require substantial execution, making near-term operating performance highly dependent on successful product integration and market expansion.
Persistent Cash BurnRepeatedly negative operating and free cash flow indicates that the business is not yet self-funding. Continued cash consumption can constrain investment in commercialization and pipeline programs, while increasing reliance on external financing or asset sales to sustain operations.
Commercial Deal ObligationsThe new product rights carry ongoing economic and purchasing obligations that could limit the cash contribution from future sales. Ferring also retains Rebyota manufacturing and supply, so RedHill’s commercial expansion remains tied to the agreement’s royalty, commitment, and supply framework.
RedHill Biopharma News
2RH FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was €7.33 and its highest was €8.00 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is €3.79M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Mar 18, 2027 which is in 191 days.
How were RedHill Biopharma’s earnings last quarter?
RedHill Biopharma released its earnings results on Sep 05, 2025. The company reported -€1.986 earnings per share for the quarter.
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 6,080,920 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
RedHill Biopharma reported an EPS of -€1.986 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in DE:2RH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Technical Analysis
Ironwood Pharma
―
Perrigo Company
―
SIGA Technologies
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―